Skip to main content

Advertisement

SpringerLink
Log in

In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998–2007

  • Article
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

The minimum inhibitory concentrations (MICs) of 330 nonduplicate Helicobacter pylori isolates to nemonoxacin, tigecycline, and eight other antimicrobial agents were determined by using the agar dilution method. Sequencing the quinolone resistance-determining regions (QRDRs) in the gyrA gene of these isolates was also performed. Resistance to clarithromycin showed an increasing trend during the ten-year study period and was highest (38%) in 2005. Tigecycline had potent in vitro activities against all isolates, with an MIC90 of 0.06 μg/ml. Among the quinolones tested, nemonoxacin (MIC50 of 0.12 μg/ml and MIC90 of 0.25 μg/ml) and gemifloxacin had one to two-fold better in vitro activities than ciprofloxacin, levofloxacin, and moxifloxacin. Among the nine isolates (2.7%) with levofloxacin resistance, four (44.4%) were also resistant to metronidazole, three (33.3%) to clarithromycin, and two (22.2%) to amoxicillin. Isolates with levofloxacin resistance exhibited one or two of three amino acid alterations (Ser-70, Asn-87, and Asp-91) involved in QRDRs in the gyrA gene. A double mutation at Ser70Cys and Asn87Ile had a higher level of resistance. The results of this study suggest a potentially useful role of nemonoxacin and tigecycline in the treatment of infections caused by H. pylori. The gyrA mutation at Ser-70 is a novel finding and has an impact on levofloxacin resistance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Chey WD, Wong BC; Practice Parameters Committee of the American College of Gastroenterology (2007) American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 102:1808–1825

    Article  CAS  PubMed  Google Scholar 

  2. Malfertheiner P, Mégraud F, O’Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ (2007) Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 56:772–781

    Article  CAS  PubMed  Google Scholar 

  3. Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, Lam SK, Xiao SD, Tan HJ, Wu CY, Jung HC, Hoang BH, Kachintorn U, Goh KL, Chiba T, Rani AA; Second Asia-Pacific Conference (2009) Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 24:1587–1600

    Article  PubMed  Google Scholar 

  4. Mégraud F (2004) H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 53:1374–1384

    Article  PubMed  Google Scholar 

  5. Vakil N, Mégraud F (2007) Eradication therapy for Helicobacter pylori. Gastroenterology 133:985–1001

    Article  CAS  PubMed  Google Scholar 

  6. Nista EC, Candelli M, Zocco MA, Cremonini F, Ojetti V, Finizio R, Spada C, Cammarota G, Gasbarrini G, Gasbarrini A (2006) Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication. Am J Gastroenterol 101:1985–1990

    Article  CAS  PubMed  Google Scholar 

  7. Saad RJ, Schoenfeld P, Kim HM, Chey WD (2006) Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol 101:488–496

    Article  CAS  PubMed  Google Scholar 

  8. Kuo CH, Hu HM, Kuo FC, Hsu PI, Chen A, Yu FJ, Tsai PY, Wu IC, Wang SW, Li CJ, Weng BC, Chang LL, Jan CM, Wang WM, Wu DC (2009) Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial. J Antimicrob Chemother 63:1017–1024

    Article  CAS  PubMed  Google Scholar 

  9. Wong WM, Gu Q, Chu KM, Yee YK, Fung FM, Tong TS, Chan AO, Lai KC, Chan CK, Wong BC (2006) Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. Aliment Pharmacol Ther 23:421–427

    Article  CAS  PubMed  Google Scholar 

  10. Yoon H, Kim N, Lee BH, Hwang TJ, Lee DH, Park YS, Nam RH, Jung HC, Song IS (2009) Moxifloxacin-containing triple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate. Helicobacter 14:77–85

    Article  CAS  PubMed  Google Scholar 

  11. Bogaerts P, Berhin C, Nizet H, Glupczynski Y (2006) Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium. Helicobacter 11:441–445

    Article  CAS  PubMed  Google Scholar 

  12. Cattoir V, Nectoux J, Lascols C, Deforges L, Delchier JC, Mégraud F, Soussy CJ, Cambau E (2007) Update on fluoroquinolone resistance in Helicobacter pylori: new mutations leading to resistance and first description of a gyrA polymorphism associated with hypersusceptibility. Int J Antimicrob Agents 29:389–396

    Article  CAS  PubMed  Google Scholar 

  13. Glocker E, Stueger HP, Kist M (2007) Quinolone resistance in Helicobacter pylori isolates in Germany. Antimicrob Agents Chemother 51:346–349

    Article  CAS  PubMed  Google Scholar 

  14. Hung KH, Sheu BS, Chang WL, Wu HM, Liu CC, Wu JJ (2009) Prevalence of primary fluoroquinolone resistance among clinical isolates of Helicobacter pylori at a University Hospital in Southern Taiwan. Helicobacter 14:61–65

    Article  CAS  PubMed  Google Scholar 

  15. Kim JM, Kim JS, Kim N, Jung HC, Song IS (2005) Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients. J Antimicrob Chemother 56:965–967

    Article  CAS  PubMed  Google Scholar 

  16. Minehart HW, Chalker AF (2001) In vitro activity of gemifloxacin against Helicobacter pylori. J Antimicrob Chemother 47:360–361

    Article  CAS  PubMed  Google Scholar 

  17. Adam HJ, Laing NM, King CR, Lulashnyk B, Hoban DJ, Zhanel GG (2009) In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. Antimicrob Agents Chemother 53:4915–4920

    Article  CAS  PubMed  Google Scholar 

  18. Chen YH, Liu CY, Lu JJ, King CH, Hsueh PR (2009) In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan. J Antimicrob Chemother 64:1226–1229

    Article  CAS  PubMed  Google Scholar 

  19. Lai CC, Tan CK, Lin SH, Liao CH, Chou CH, Hsu HL, Huang YT, Hsueh PR (2009) Comparative in vitro activities of nemonoxacin, doripenem, tigecycline and 16 other antimicrobials against Nocardia brasiliensis, Nocardia asteroides and unusual Nocardia species. J Antimicrob Chemother 64:73–78

    Article  CAS  PubMed  Google Scholar 

  20. Tan CK, Lai CC, Liao CH, Chou CH, Hsu HL, Huang YT, Hsueh PR (2009) Comparative in vitro activities of the new quinolone nemonoxacin (TG-873870), gemifloxacin and other quinolones against clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother 64:428–429

    Article  CAS  PubMed  Google Scholar 

  21. Lin L, Chang LW, Tsai CY, Hsu CH, Chung DT, Aronstein WS, Ajayi F, Kuzmak B, Lyon RA (2010) Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. Antimicrob Agents Chemother 54:405–410

    Article  CAS  PubMed  Google Scholar 

  22. Yang JC, Wang TH, Wang HJ, Kuo CH, Wang JT, Wang WC (1997) Genetic analysis of the cytotoxin-associated gene and the vacuolating toxin gene in Helicobacter pylori strains isolated from Taiwanese patients. Am J Gastroenterol 92:1316–1321

    CAS  PubMed  Google Scholar 

  23. Yang JC, Yang YF, Uang YS, Lin CJ, Wang TH (2009) Pharmacokinetic–pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori. Br J Clin Pharmacol 67:503–510

    Article  CAS  PubMed  Google Scholar 

  24. Clinical and Laboratory Standards Institute (CLSI) (2009) Performance standards for antimicrobial susceptibility testing; nineteenth informational supplement. M100-S19. CLSI, Wayne, PA

  25. Fujimura S, Kato S, Iinuma K, Watanabe A (2004) In vitro activity of fluoroquinolone and the gyrA gene mutation in Helicobacter pylori strains isolated from children. J Med Microbiol 53:1019–1022

    Article  CAS  PubMed  Google Scholar 

  26. Boyanova L, Mitov I (2010) Geographic map and evolution of primary Helicobacter pylori resistance to antibacterial agents. Expert Rev Anti Infect Ther 8:59–70

    Article  CAS  PubMed  Google Scholar 

  27. Horiki N, Omata F, Uemura M, Suzuki S, Ishii N, Iizuka Y, Fukuda K, Fujita Y, Katsurahara M, Ito T, Cesar GE, Imoto I, Takei Y (2009) Annual change of primary resistance to clarithromycin among Helicobacter pylori isolates from 1996 through 2008 in Japan. Helicobacter 14:86–90

    Article  CAS  PubMed  Google Scholar 

  28. Miyachi H, Miki I, Aoyama N, Shirasaka D, Matsumoto Y, Toyoda M, Mitani T, Morita Y, Tamura T, Kinoshita S, Okano Y, Kumagai S, Kasuga M (2006) Primary levofloxacin resistance and gyrA/B mutations among Helicobacter pylori in Japan. Helicobacter 11:243–249

    Article  CAS  PubMed  Google Scholar 

  29. Kim JM, Kim JS, Jung HC, Kim N, Kim YJ, Song IS (2004) Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea. Antimicrob Agents Chemother 48:4843–4847

    Article  CAS  PubMed  Google Scholar 

  30. Perez Aldana L, Kato M, Nakagawa S, Kawarasaki M, Nagasako T, Mizushima T, Oda H, Kodaira J, Shimizu Y, Komatsu Y, Zheng R, Takeda H, Sugiyama T, Asaka M (2002) The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance. Helicobacter 7:306–309

    Article  CAS  PubMed  Google Scholar 

  31. Chang WL, Sheu BS, Cheng HC, Yang YJ, Yang HB, Wu JJ (2009) Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycin-based therapy in Taiwan. J Gastroenterol Hepatol 24:1230–1235

    Article  CAS  PubMed  Google Scholar 

  32. Moore RA, Beckthold B, Wong S, Kureishi A, Bryan LE (1995) Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori. Antimicrob Agents Chemother 39:107–111

    CAS  PubMed  Google Scholar 

  33. Tankovic J, Lascols C, Sculo Q, Petit JC, Soussy CJ (2003) Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori. Antimicrob Agents Chemother 47:3942–3944

    Article  CAS  PubMed  Google Scholar 

  34. Romano M, Iovene MR, Russo MI, Rocco A, Salerno R, Cozzolino D, Pilloni AP, Tufano MA, Vaira D, Nardone G (2008) Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical isolates. J Clin Pathol 61:1112–1115

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan

    J.-C. Yang

  2. Department of Pediatrics, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan

    P.-I. Lee

  3. Departments of Laboratory Medicine and Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, No. 7, Chung-Shan South Road, 100, Taipei, Taiwan

    P.-R. Hsueh

Authors
  1. J.-C. Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P.-I. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P.-R. Hsueh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P.-R. Hsueh.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yang, JC., Lee, PI. & Hsueh, PR. In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998–2007. Eur J Clin Microbiol Infect Dis 29, 1369–1375 (2010). https://doi.org/10.1007/s10096-010-1009-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-010-1009-9

Keywords

Search

Navigation